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y 31, 2013.he aim of this study was to determine whether response to prasugrel is associated with the proportion of circulating
reticulated platelets (RPs) in patients with ST-segment elevation myocardial infarction (STEMI).Background Despite better pharmacodynamic properties and clinical efﬁcacy of prasugrel compared with clopidogrel,
antiplatelet responses to prasugrel are not uniform. The mechanism of this variability in response is not clear. RPs,
young hyperactive forms, are increased during situations of enhanced platelet turnover.Methods Patients with STEMI treated with primary percutaneous intervention (PCI) and prasugrel were tested for platelet
reactivity using purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) assay and multiple electrode aggregometry
(MEA). RP levels were determined using ﬂow cytometry with thiazole orange staining. Tests were performed at 2 to
4 days and 30 days post-PCI. Platelet function was compared by varying levels of RPs, analyzed as continuous
(regression analysis) and categorical (tertiles) variables.Results Sixty-two patients were included (mean age: 57.5  8 years; 21.2% women; 27.7% diabetes). At the early time
point, RP levels were strongly correlated with platelet reactivity when evaluated by the P2Y12 assay (Spearman’s
correlation coefﬁcient: 0.55 for P2Y12 reaction units, –0.49 for percent inhibition) and MEA (Spearman’s: 0.50). The
upper tertile of RPs displayed higher platelet reactivity compared with the middle and lower tertiles, according to
P2Y12 assay and MEA. Similar results with strong correlations between RP and platelet reactivity were noted at
30 days post-PCI.Conclusions The proportion of circulating RPs strongly correlates with response to prasugrel in patients with STEMI treated with
PCI. High levels of RPs are associated with increased platelet reactivity despite prasugrel treatment. (J Am Coll
Cardiol 2014;63:513–7) ª 2014 by the American College of Cardiology FoundationEarly pharmacodynamic studies of prasugrel have indicated
potent and consistent platelet inhibition, with relatively low
rates of high on-treatment platelet reactivity (HTPR) during
treatment compared with clopidogrel (1,2). Despite these
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prasugrel treatment is present in approximately one-fourth
of patients with acute coronary syndromes and is associ-
ated with an increased risk of adverse cardiac events (3).See page 518In the TRITON–TIMI 38 (Trial to Assess Improvement
in Therapeutic Outcomes by Optimizing Platelet Inhibi-
tion with Prasugrel–Thrombolysis In Myocardial Infarction
38) pharmacodynamic substudy (4), roughly 25% to 30% of
patients had HTPR 1 to 2 h after the prasugrel loading dose,
which decreased to 10% at 30 days. Similarly, in recent
studies in patients with ST-segment elevation myocardial
infarction (STEMI), HTPR rates 2 h after prasugrel loading
Figure 1 Study Design and
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514were 35% to 44% and decreased
signiﬁcantly thereafter (5,6). Thus,
there appears to be a certain degree
of clinically signiﬁcant variability
in response to prasugrel therapy,
albeit signiﬁcantly less than that
observed with clopidogrel.
The causes underlying the vari-
ability in prasugrel’s antiplatelet
effects are presently unclear.
Genetic studies initially reported
that, in contrast to clopidogrel,
variations in the genes encod-
ing cytochrome P450 (CYP)
2C19 and the adenosine triphos-
phate–binding cassette transporterABCB1 (CYP2C19 and ABCB1) do not affect the response to
prasugrel (7,8). However, a recent report did indicate an
inﬂuence ofCYP2C19*2 and *17 alleles on response toprasugrel
(9). It is possible that intrinsic platelet factors, rather than
factors inﬂuencing the metabolic conversion of the drug, are
responsible for the variability in response. Reticulated platelets
(RPs) represent younger, more hyperactive platelets, with
increased volume and a greater number of dense granules than
older circulating platelets (10).RPshavebeen shown to increaseOverview
ts undergoing primary percutaneous intervention (PC
R ¼ high on-treatment platelet reactivity; MEA ¼ mulin situations of increased platelet turnover, such as acute coro-
nary syndromes (11) and stroke (12). We have previously
shown that the proportion of circulating RPs inversely corre-
lates with clopidogrel responsiveness in patients with stable
coronary artery disease (13). Accordingly, our aim was
to evaluate whether response to prasugrel is associated with
the proportion of RPs in the circulation in patients with
STEMI undergoing primary percutaneous coronary interven-
tion (PCI).Methods
Patients. Patients undergoing primary PCI for STEMI
in the Rabin Medical Center, Petah-Tikva, Israel, were
considered for study participation. Patients were excluded
in cases of speciﬁc contraindications to prasugrel (age
>75 years, weight <60 kg, or a history of stroke or transient
ischemic attack). Other exclusion criteria included hemody-
namic instability, thrombocytopenia (<100,000 cells/mm3),
anemia (hemoglobin <10 g/dl), and renal failure (creatinine
>2.5 mg/dl).
Study protocol. All patients were treated with prasugrel
60 mg and aspirin 325 mg before the cardiac catheterization
and received daily prasugrel 10 mg and aspirin 100 mg
thereafter. Adjunctive treatment during PCI was givenI) for ST-segment elevation myocardial infarction (STEMI) in this study.
tiple electrode aggregometry.
Table 1
Baseline Characteristics of the Study Population
(N ¼ 62)*
Demographic characteristics
Age (yrs) 57.5  8.0
Female 21.2
Body mass index (kg/m2) 28.6  4.8
Clinical characteristics
Hyperlipidemia 59.1
Smokingy 51.5
Hypertension 43.9
Diabetes mellitus 27.7
Prior myocardial infarction 21.2
Prior CABG 6.1
Laboratory ﬁndings
Hemoglobin (g/dl) 11.9  1.8
Platelets (103 per mm3) 248.2  71.4
Mean platelet volume (ﬂ) 9.3  1.1
Creatinine (mg/dl) 1.22  0.6
Medications at discharge
Statin 93.9
ACE inhibitor 92.4
Beta-blocker 81.8
Proton-pump inhibitor 53.0
Peri-procedural GPIIB-IIIA inhibitor 6.1
Values are mean  SD or %. *All patients had ST segment elevation myocardial infarction. yCurrent
or former smokers.
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft surgery;
GP ¼ glycoprotein.
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515according to physician discretion. Patients were tested at
2 time points: 1. 2 to 4 days post-PCI, just before hospital
discharge; and 2. 30 days post-PCI. The overall study design
is summarized in Figure 1. At each time point, platelet
reactivity was determined using the VerifyNow purinergic
receptor P2Y, G-protein coupled, 12 (P2Y12) platelet func-
tion assay (Accumetrics, San Diego, California) andFigure 2
Correlation Between Reticulated Platelets and
Platelet Function
This regression analysis was performed on combined data from both time points.
Scatterplot of reticulated platelets versus P2Y12 (in P2Y12 reaction units [PRU])
with a Spearman’s rank correlation coefﬁcient of 0.57.multiple electrode aggregometry (MEA) with the Multiplate
analyzer (Dynabyte, Munich, Germany). Platelet reactivity is
expressed in P2Y12 reaction units (PRU), percent inhibition,
and aggregation units, respectively.
RP levels were determined at the 2 time points by using
a ﬂow cytometric assay, as previously described (14). Brieﬂy,
whole blood was incubated with thiazole orange or isotonic
diluent (IsoFlow, Coulter Diagnostics, Hialeah, Florida) as
control. The incubated blood was spun to form a cellular
pellet, which was resuspended in isotonic diluent. Flow
cytometry was performed counting 10,000 platelets in the
platelet gate. RPs are expressed as percentage of total
platelets counted.
Statistical analysis. Data are presented as mean  SD
unless otherwise speciﬁed. Platelet function was compared
by varying levels of RPs, analyzed as a continuous (regression
analysis) and categorical (tertile-based analysis) variable.
We utilized recently published deﬁnitions for HTPR for
both platelet assays (47 aggregation units for MEA
and 208 PRU for P2Y12 assay) (14,15). Spearman’s rank
correlation coefﬁcients (r) were used to describe the rela-
tionship between platelet function (MEA or P2Y12 assay)
and levels of RPs. Platelet reactivity (for both assays) was
also compared across RP tertiles using analysis of variance
testing. Analyses were performed using SPSS version 12
(SPSS Inc., Chicago, Illinois). Statistical signiﬁcance was set
at p < 0.05.Results
Baseline characteristics. Sixty-two patients with STEMI
treated with primary PCI were initially included (mean age:
57.5  8 years; 21.2% women; 27.7% diabetes). Sixteen
patients were lost to follow-up and thus 46 patients were
included in the follow-up analysis. Table 1 describes the
baseline characteristics of the entire cohort (N ¼ 62).
Rates of HTPR. At 2 to 4 days post-PCI, 8.1% of the
patients were considered HTPR according to the P2Y12
assay and 11.3% according to MEA. At follow-up at 30
days, rates of HTPR were similar at 9.1% and 11.4%,
respectively (Fig. 1).
Relationship between RPs and platelet reactivity. At 2 to
4 days post-PCI, the levels of RP were strongly correlated
with platelet reactivity when evaluated by the P2Y12 assay
(r ¼ 0.55 for PRU; –0.49 for percent inhibition; p < 0.0001)
and MEA (r ¼ 0.50; p < 0.0001). Similar correlations were
observed at 30 days post-PCI (r ¼ 0.65 and –0.57 for P2Y12
assay [p < 0.0001] and 0.44 for MEA [p ¼ 0.004]).
Figure 2 displays a representative scatterplot for the corre-
lation between RPs and P2Y12 assay (PRU) when the data
from both time points were grouped together.
In the categorical analysis (Fig. 3), at the early time point
the upper tertile of RP displayed higher platelet reactivity
when compared with the middle and lower tertiles,
according to the P2Y12 assay (PRU and percent inhibition)
and MEA (p  0.01 for all assays) (Fig. 3A). Similar trends
Figure 3 Platelet Reactivity by Reticulated Platelet Tertile
Comparisons across the 3 tertiles were performed using 1-way analysis of variance after percutaneous intervention at days 2 to 4 (A) (n ¼ 62) and day 30 (B) (n ¼ 46).
Values are mean  SE. VF ¼ VerifyNow P2Y12 platelet function assay (Accumetrics, San Diego, California); other abbreviations as in Figures 1 and 2.
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516were noted at the 30-day post-PCI time point, although the
differences between the 3 RP tertiles in MEA values were
not signiﬁcant (Fig. 3B). The average level of RPs was
higher at the early time point compared to the 30-day
follow-up time point (18.6  18% vs. 13.6  10%;
p ¼ 0.04).Discussion
Our study is the ﬁrst to examine the association between
response to prasugrel and the level of circulating RPs as
a possible mechanism for the variability in response to the
drug. It provides 2 important insights to our understanding
of antiplatelet responses in patients with STEMI: 1)
approximately 10% of our sample were subject to persistently
on-treatment platelet reactivity despite prasugrel treatment
for a few days to a month after treatment initiation; and 2)
RPs, young, hyperactive platelet subpopulations, are strongly
related to residual platelet reactivity in prasugrel-treated
patients in a dose-dependent fashion.
Variability in prasugrel response. Our study is in
concordance with prior studies that have suggested that
HTPR in face of peri-procedural prasugrel therapy is not an
uncommon phenomenon in acute coronary syndromes
(4–6). It is noteworthy that compared to those in prior trials,
rates of HTPR in our study were relatively lower (9% to 11%
compared with roughly 25% in prior experiences [3–6]).
These differences in HTPR rates may reﬂect variation in
the timing of the examinations. We waited at least 48 h
after prasugrel loading before platelet function measurement,
whereas earlier time points (2 to 12 h post-loading dose)
were utilized in previous studies (3–6). Importantly, when
platelet assays were repeated at 30 days post-procedure, rates
of HTPR were comparable to those reported in our inves-
tigation (4). Slight variations in the deﬁnitions of HTPR
and the use of different platelet function assays across these
studies may have also contributed to the differences in point
estimates of HTPR.Reticulated platelets. We previously demonstrated an
association between increased platelet reactivity and the
proportion of circulating RPs in healthy volunteers after
aspirin administration (16) and in patients with stable
coronary artery disease receiving dual antiplatelet therapy
with aspirin and clopidogrel (13). This study extends these
ﬁndings to a population of prasugrel-treated STEMI
patients. It is believed that RPs are more physiologically
active (10,17). It is possible that these cells contain mRNA
(18), which enables the expression of increased amounts of
adenosine diphosphate receptors and intragranular proteins.
These intrinsic platelet products may explain the observed
increased reactivity and reduced responsiveness to anti-
platelet therapy (10,16).
Study limitations. The study ﬁndings should be considered
in the context of several potential limitations. The relatively
low number of enrolled patients limits causal conclusions
about the role of RPs in contributing to HTPR. Unfor-
tunately, the rate of patients lost to follow-up (w25%) at
30 days may have introduced additional bias into the
study results. Furthermore, the study was not powered to
assess clinical endpoints; thus, the true clinical implications
of our ﬁndings are unclear. The deﬁnitions employed for
prasugrel HTPR were based on thresholds validated for
clopidogrel treatment (14,15). Finally, platelet function
was not determined in this study using the gold standard
light-transmission aggregometry. However, both MEA
and P2Y12 assay perform well, and in relatively good
agreement with light-transmission aggregometry, in assess-
ing platelet reactivity during P2Y12 inhibition (14).Conclusions
The proportion of circulating RPs strongly and inversely
correlates with response to prasugrel in patients with STEMI
treated with primary PCI. High levels of RPs are associated
with increased platelet reactivity despite prasugrel treatment.
Future larger studies assessing the clinical signiﬁcance and
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517prognostic value of the levels of circulating RPs and residual
platelet reactivity in patients with STEMI treated with pra-
sugrel are warranted.
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